News & Events about Gamida Cell Ltd.
Ticker Report
2 months ago
Gamida Cell (NASDAQ:GMDA Get Rating) had its price objective cut by equities researchers at Needham Company LLC from $9.00 to $8.00 in a research note issued to investors on Tuesday, MarketBeat Ratings reports. The firm currently has a buy rating on the stock. Needham &#...
Business Wire
2 months ago
Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today announced that members of the management team will present at the following upcoming investor conferences: 34th Annual Piper...
Business Wire
2 months ago
Gamida Cell Ltd. (Nasdaq: GMDA), the global leader in the development of NAM-enabled cell therapies for patients with solid and hematological cancers and other serious diseases, today announced encouraging preclinical data on GDA-501, a genetically modified NAM (nicotinamide) Natural Killer (NK...
Business Wire
2 months ago
Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today announced that the company will host a conference call and live audio webcast on Monday, November 14, 2022, at 8:00 AM EST...
Business Wire
3 months ago
Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, announces that Michele Korfin, Chief Operating Officer and Chief Commercial Officer, will present its corporate...